Eisai Company Ltd (ESALY)

[buzz lightyear]

News for 'ESALY' - (Eisai Announces Availability of Halaven(R) (eribulin) in Kuwait)


HATFIELD, England, Jul 28, 2013 (PR Newswire Europe via COMTEX) -- HATFIELD,
England, July 29, 2013 /PRNewswire/ --

Partnership deal secured with Yiaco for Kuwait distribution

Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) today announces
its partnership with Kuwait's leading pharmaceutical marketing agency, Yiaco
Medical Company, for the distribution of Halaven(R) (eribulin), for the
treatment of patients with locally advanced or metastatic breast cancer, who
have progressed after at least two chemotherapeutic regimens for advanced
disease.

Commenting on the availability of eribulin in Kuwait, Toshitaka Asano, Vice
President Market Development Business Unit EMEA, said: "The distribution of
Halaven in Kuwait is part of Eisai's wider strategy of establishing a solid
foundation in the EMEA region. We recognise Kuwait as a strong and stable market
in the region which has a rapidly growing population with very specific
healthcare needs. Our valued partnership with Yiaco Medical Company will mean
people can receive rapid access to innovative treatments not previously
available to them."

Kuwait is recognised as one of the best-regulated pharmaceutical markets of the
Gulf Cooperation Council (GCC) and remains the second most attractive
pharmaceutical market in the region according to the latest Business Monitor
International (BMI) Risk / Reward Ratings (RRR) analysis.[1] Continued market
growth is anticipated over the next five years, buoyed up by both a high birth
rate and an expanding population, offering the industry a relatively stable
environment in which to operate.[1]

"As the market-leading pharmaceutical distributor in Kuwait, we are excited
about the opportunity to work in partnership with Eisai to distribute Halaven in
this region," said Tareq Alryan, Assistant CEO, Pharma and Business Development,
at Yiaco Medical Company. "Our unrivalled market knowledge and reputation in the
region allows us to support Eisai in launching Halaven in Kuwait, whilst at the
same time addressing the health needs of patients and their families in Kuwait."

Eribulin is now commercially available in Kuwait and received the full
registration in October 2012.

As part of Eisai's globalisation strategy set out in its mid-term strategic plan
in 2011 "HAYABUSA", the company seeks to expand its global presence by 2015 in
an effort to achieve its objective of making contributions to more than 500
million patients worldwide. Since its launch in the European Union in March
2011, eribulin is now widely available worldwide.

ENDS

Notes to Editors

About Eisai's Commitment to Improving Global Access to Medicines

Today, it is estimated that some 2.7 billion* people around the world live on
US$ 2 or less per day. Most of these 2.7 billion people do not have access to
essential health care and treatment despite the availability of effective
medicines. This is an international challenge that needs to be solved through
collaborations among governments, international organisations such as the WHO,
non-governmental organisations and pharmaceutical companies.

In line with its human health care (hhc) mission, Eisai is committed to
improving global access to medicines over the medium-to-long term through
partnership strategies that involve working with governments, international
organisations, private entities and non-profit organisations. Specifically, the
company has developed and is implementing a five-target approach to improve
access to medicines worldwide. The five key components are: product creations,
strategic solutions, capacity building, quality innovation, and long-term
investment.

For further information on Eisai's Access to Medicines initiatives, please visit
the Access to Medicines page on the Eisai Global
website:http://www.eisai.com/company/atm/index.html

* Source: World Bank (2005)

About Eisai

Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas:



- Oncology including: anticancer therapies; tumour regression, tumour

suppression, antibodies, etc

- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss

- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid

arthritis, psoriasis, and inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan,
Eisai employs more than 10,000 people worldwide. From its Knowledge Centre in
Hatfield, UK, Eisai has recently expanded its business operations to include
Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales
and marketing operations in over 20 markets, including the United Kingdom,
France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark,
Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium,
the Middle East and Russia.

For further information please visit: http://www.eisai.co.uk

About Yiaco

Yiaco Medical Company was established in the year 1953 as a sole marketing agent
for many multinational research-based pharmaceutical manufacturers. Yiaco
quickly grew with the boom in Kuwait's own national growth and development,
diversifying and expanding into other healthcare services such as Medical
Equipment, Hospital supplies and Dental equipment & materials. Through its many
years of operation and experience in the medical field, Yiaco's reputation of
excellence precedes its name. A name that has come to mean undisputed market
leadership in the area of medical care, unparalleled sales and services, as well
as innovative state-of-the-art technology for the medical and healthcare fields.

Yiaco is fully committed to the modern healthcare system in Kuwait and abroad;
and through this commitment, it has earned the privilege of delivering
intelligent and economic solutions to the medical profession and the public.
This commitment is not only evident through its ability to equip entire
hospitals and research centers from the ground up, but in its solid financial
holdings and a proud family of employees.

1. Business Monitor International: Industry Risk / Reward Ratings - Kuwait - Q2,
2013



Date of preparation: July 2013

Job Code: Halaven-UK0146


CONTACT: CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson / CharlotteAndrews,

[phone] / [phone],[e-mail],

[e-mail] ; Tonic LifeCommunications, Siobhan Reilly / April

Kenneally, [phone] / [phone], [e-mail]

, [e-mail]; For further information on Yiaco Medical Company

in Kuwait, pleasecontact: Tareq Alryan - Assistant CEO, Pharma and Business

Development,Yiaco , [phone], [e-mail]. For further

information onYiaco Medical Company in Kuwait, please contact: Tareq Alryan -

AssistantCEO, Pharma and Business Development, Yiaco,

[phone],[e-mail]




Copyright (C) 2013 PR Newswire Europe

-0-




SUBJECT CODE: PDT

Topic

BIO

Topic

HEA

Topic

MTC

Topic

United Kingdom

Iran

Iraq

Israel

Jordan

Kuwait

Lebanon

Saudi Arabia

Syria

Bahrain

Palestine

Qatar

Yemen

Oman

United Arab Emirates